TY - JOUR
T1 - CD226 is specifically expressed on the surface of Th1 cells and regulates their expansion and effector functions
AU - Dardalhon, Valerie
AU - Schubart, Anna S.
AU - Reddy, Jayagopala
AU - Meyers, Jennifer Hartt
AU - Monney, Laurent
AU - Sabatos, Catherine A.
AU - Ahuja, Rakesh
AU - Nguyen, Khuong
AU - Freeman, Gordon J.
AU - Greenfield, Edward A.
AU - Sobel, Raymond A.
AU - Kuchroo, Vijay K.
PY - 2005/8/1
Y1 - 2005/8/1
N2 - Surface molecules that are differentially expressed on Th1 and Th2 cells may be useful in regulating specific immune responses in vivo. Using a panel of mAbs, we have identified murine CD226 as specifically expressed on the surface of differentiated Th1 cells but not Th2 or Th0 cells. Although CD226 is constitutively expressed on CD8 cells, it is up-regulated on CD4 cells upon activation. Th1 differentiation results in enhanced CD226 expression, whereas expression is down-regulated upon Th2 polarization. We demonstrate that CD226 is involved in the regulation of T cell activation; in vivo treatment with anti-CD226 results in significant reduction of Th1 cell expansion and in the induction of APCs that inhibit T cell activation. Furthermore, anti-CD226 treatment delays the onset and reduces the severity of a Th1-mediated autoimmune disease, experimental autoimmune encephalomyelitis. Our data suggest that CD226 is a costimulatory molecule that plays an important role in activation and effector functions of Th1 cells.
AB - Surface molecules that are differentially expressed on Th1 and Th2 cells may be useful in regulating specific immune responses in vivo. Using a panel of mAbs, we have identified murine CD226 as specifically expressed on the surface of differentiated Th1 cells but not Th2 or Th0 cells. Although CD226 is constitutively expressed on CD8 cells, it is up-regulated on CD4 cells upon activation. Th1 differentiation results in enhanced CD226 expression, whereas expression is down-regulated upon Th2 polarization. We demonstrate that CD226 is involved in the regulation of T cell activation; in vivo treatment with anti-CD226 results in significant reduction of Th1 cell expansion and in the induction of APCs that inhibit T cell activation. Furthermore, anti-CD226 treatment delays the onset and reduces the severity of a Th1-mediated autoimmune disease, experimental autoimmune encephalomyelitis. Our data suggest that CD226 is a costimulatory molecule that plays an important role in activation and effector functions of Th1 cells.
UR - http://www.scopus.com/inward/record.url?scp=22544455033&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=22544455033&partnerID=8YFLogxK
U2 - 10.4049/jimmunol.175.3.1558
DO - 10.4049/jimmunol.175.3.1558
M3 - Article
C2 - 16034094
AN - SCOPUS:22544455033
SN - 0022-1767
VL - 175
SP - 1558
EP - 1565
JO - Journal of Immunology
JF - Journal of Immunology
IS - 3
ER -